Chapter 5 - THE TRIAL THAT NEVER EXISTED
Arthur Carter welcomed Evelyn into his office as though she had come for an ordinary family disagreement. He stood beside a wall of photographs showing hospital wings, scholarship recipients, and research centers bearing the Carter name. At seventy, he still carried himself like the man who built a pharmaceutical manufacturing company into an international medical enterprise.
“I heard you saw Lily,” he said.
Evelyn did not sit.
“You already knew where she was.”
Arthur glanced toward the photograph she placed on his desk.
“Private security identified a child who might have been Lily. We were verifying it before upsetting you.”
“You had three months.”
“And you had six years of false leads. I wasn’t going to put you through another one.”
The explanation would once have worked. Evelyn had spent years relying on Arthur’s investigators, Arthur’s attorneys, and Arthur’s money. He organized searches across multiple states, hired former federal agents, and promised repeatedly that he would bring Lily home.
Now she wondered how many of those searches were real.
She asked directly whether Carter Biomedical administered an investigational drug to Lily without permission.
Arthur’s expression changed.
“The doctors were trying to save her.”
“That is not what I asked.”
“It was a complicated medical emergency.”
“Did you authorize the treatment?”
Arthur sat down.
He did not answer.
Evelyn left before he could turn the conversation toward Daniel’s dishonesty.
The first major reveal came that evening through an independent medical reviewer. The drug Lily received was part of a pediatric research program Carter Biomedical had suspended after several adverse events. It was never approved for general use in children with Lily’s condition.
The company had submitted a narrower study protocol to regulators.
Lily did not meet its eligibility criteria.
She was not enrolled as a legitimate trial participant.
Someone administered the medication outside the approved study and later tried to attach her case to the research records.
The reviewer found an internal safety memorandum dated eleven days before Lily’s hospitalization. It warned that the drug could cause severe reactions in children with a particular cardiac marker.
Lily had that marker.
Her hospital file contained the test result.
Evelyn read the memorandum until the words blurred.
“Who signed this?”
The approving executive was Arthur Carter.
He knew the danger before the treatment.
That did not prove he intended Lily harm. It proved he authorized the company’s knowledge of a risk that should have changed clinical decisions.
The financial motive emerged in the next file. Carter Biomedical was negotiating a major research partnership at the time. A serious unauthorized pediatric exposure could have jeopardized financing, regulatory approvals, and several executive compensation packages.
Arthur stood to lose tens of millions.
The company also faced potential criminal and civil exposure if investigators concluded consent records had been falsified.
Daniel’s disappearance suddenly had a broader context.
Returning Lily would revive the medical questions Arthur wanted closed.
But the reveal created a deeper contradiction.
If Arthur wanted the treatment scandal buried, why search for Lily at all?
Why photograph her three months earlier rather than leave her hidden?
Evelyn found part of the answer in Carter Family Office records. Six months earlier, Lily’s original hospitalization had been selected for a retrospective safety audit connected to Carter Biomedical’s proposed acquisition by a larger pharmaceutical company.
The acquiring company requested every serious pediatric adverse event.
Lily’s file was incomplete.
Auditors wanted to locate the patient.
Arthur had known the search would eventually lead to her.
May you like
He was not merely looking for a granddaughter.
He was trying to reach a witness before independent investigators did.
